18 results
8-K
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
in tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
and elicited tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple
10-K
40gyw41ct3yio2u0
10 Mar 21
Annual report
4:12pm
424B4
ligp6jcxn56fxi5cycc
12 Feb 21
Prospectus supplement with pricing info
4:23pm
DRS
6rie3g7e88nrwib 1w
28 Jan 21
Draft registration statement
12:00am
10-Q
j6xtykusa7xuy3
12 Nov 20
Quarterly report
8:01am
424B4
5pl 5er4p3c
2 Oct 20
Prospectus supplement with pricing info
12:00am
S-1
yjmi9p
11 Sep 20
IPO registration
4:49pm
DRS/A
ixehh039s5anjyikm
26 Aug 20
Draft registration statement (amended)
12:00am
DRS/A
0m1lzyk7cs s4cw8
29 Jul 20
Draft registration statement (amended)
12:00am
DRS/A
eukxx2y6g1y2b4xsfw
20 Dec 19
Draft registration statement (amended)
12:00am
DRS
v9ohuvhp
31 Oct 19
Draft registration statement
12:00am
- Prev
- 1
- Next